Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Davutamig - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Davutamig - Regeneron Pharmaceuticals

Alternative Names: REGN-5093

Latest Information Update: 03 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 13 Sep 2024 Interim adverse events and efficacy data from a phase-I/II trial in Non-small-cell-lung-cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024), ,
  • 27 Mar 2024 Pharmacokinetics and Immunogenicity data from a phase I/II trial in Non-small cell lung cancer presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2024)
  • 04 Nov 2022 Adverse events data from a phase I/II trial in Non-small cell lung cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top